多发性硬化症和视神经脊髓炎患者血清中针对 25 种髓鞘少突胶质细胞糖蛋白表位的抗体：对诊断和疾病活动的临床价值。

Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.

机构信息

Department of Neurology, Peking Union Medical College Hospital, Beijing, China.

出版信息

Chin Med J (Engl). 2012 Sep;125(18):3207-10.

Abstract

BACKGROUND

Whether antibody to myelin oligodendrocyte glycoprotein (MOG) can be a diagnostic marker for multiple sclerosis (MS) is still controversial. Recent studies suggested that serum specific anti-MOG epitope antibody might be an MS specific marker. However, these studies did not include neuromyelitis optica (NMO) which might be proven to also have anti-MOG antibody. Hence, the present study was undertaken to investigate the clinical value of serum antibodies to 25 MOG epitopes in conventional MS (CMS) and NMO.

METHODS

Serum anti-MOG epitope IgG was detected in 61 CMS patients, 54 NMO patients, and 77 healthy controls, using enzyme-linked immunosorbent assay (ELISA).

RESULTS

Anti-MOG(27-38) IgG levels in both CMS and NMO patients were significantly higher than that in healthy controls (optical density (OD): 0.64 ± 0.38, 0.48 ± 0.23 vs. 0.19 ± 0.09; P = 0.000). CMS and NMO patients in relapse stage had significantly higher anti-MOG(27-38) IgG level than patients in remission stage (OD: 0.55 ± 0.14 vs. 0.24 ± 0.09, P = 0.027).

CONCLUSION

Although serum anti-MOG epitope IgG could not differentiate MS from NMO, it may be a useful marker for monitoring disease activity.

摘要

背景

抗髓鞘少突胶质细胞糖蛋白（MOG）抗体是否可作为多发性硬化症（MS）的诊断标志物仍存在争议。最近的研究表明，血清特异性抗 MOG 表位抗体可能是 MS 的特异性标志物。然而，这些研究并未包括视神经脊髓炎（NMO），而 NMO 可能也存在抗 MOG 抗体。因此，本研究旨在探讨血清中针对 25 个 MOG 表位的抗体在常规 MS（CMS）和 NMO 中的临床价值。

方法

采用酶联免疫吸附试验（ELISA）检测 61 例 CMS 患者、54 例 NMO 患者和 77 名健康对照者的血清抗 MOG 表位 IgG。

结果

CMS 和 NMO 患者的抗 MOG（27-38）IgG 水平均明显高于健康对照组（光密度（OD）：0.64 ± 0.38，0.48 ± 0.23 比 0.19 ± 0.09；P = 0.000）。处于复发期的 CMS 和 NMO 患者的抗 MOG（27-38）IgG 水平明显高于缓解期患者（OD：0.55 ± 0.14 比 0.24 ± 0.09，P = 0.027）。